China / United States
Every company in the roster headquartered in China / United States.
Every company in the roster headquartered in China / United States.
5 of 5 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
NovaBridge BiosciencesNBP · Nasdaq | 2 assets: 1 Ph 3, 1 Ph 2 | UliledlimabPhase 2/3 · Non-Small Cell Lung Cancer | Dec 2026givastomig · Phase 1 | $104M | $211MDec 2025 | ~38.3 qtrs | $63M |
Insilico Medicine3696 · HKEX | 1 asset: 1 Ph 2 | garutadustatPhase 2 · Ulcerative Colitis | 15 Aug 2027garutadustat · Phase 2 | — | $393MDec 2025 | ~4.5 qtrs | $81M |
Corxel PharmaceuticalsPrivate | 1 asset: 1 Ph 3 | Omecamtiv mecarbilPhase 3 · Heart FailureReliable signal | Sep 2027Omecamtiv mecarbil · Phase 3 | — | — | — | — |
Regor PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | regor GLP-1Phase 2 · ObesityPartial signal | None on record | — | — | — | — |
TheracosPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.